practiceupdate.com/C/114754...
TAKE-HOME MESSAGE
The authors of this meta-analysis of 75 trials including over 50,000 patients evaluated the performance of intermediate clinical endpoints in randomised trials enrolling patients with localised prostate cancer. Metastasis-free survival correlated strongly with overall survival. Progression-free survival showed moderate correlation with overall survival. However, biochemical failure, biochemical failure–free survival, biochemical failure and clinical failure, and local failure all correlated poorly with overall survival.
Among patients with localised prostate cancer, only metastasis-free survival was validated as a surrogate endpoint for overall survival.